Drug Discovery World
JANUARY 10, 2024
These therapies, which exhibit substantial long-term side effects, including genotoxicity and an increased predisposition to secondary cancers, have significantly higher rates of subsequent malignancies than the rate reported for patients following CAR-T cell immunotherapies.
Pharmaceutical Technology
DECEMBER 9, 2022
M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. All our equipment is in line with the latest European Medicines Agency (EMA) and FDA methods.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 8, 2021
The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We Animals were administered molnupiravir for longer and at higher doses (mg/Kg) than those employed in human studies. About Molnupiravir.
The Pharma Data
FEBRUARY 8, 2021
IBRANCE may impair fertility in males and has the potential to cause genotoxicity. At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Advise male patients to consider sperm preservation before taking IBRANCE.
The Pharma Data
MARCH 25, 2021
These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. lead researcher and Professor in Breast Cancer Excellence in the Perelman School of Medicine at the University of Pennsylvania.
Pharmaceutical Technology
JUNE 26, 2022
From a customer perspective, this means that we are able to pursue more innovative solutions, reducing overall costs and getting new medicines to market faster.". In summary, there are many challenges and considerations that drug developers must be aware of before kicking off their drug substance program.
The Pharma Data
APRIL 7, 2021
“Women with triple-negative breast cancer have historically had very few effective treatment options and faced a poor prognosis,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and global principal investigator of the ASCENT study.
Expert insights. Personalized for you.
59 
Let's personalize your content